Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial
Status:
Completed
Trial end date:
2016-12-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is through a phase I/II clinical trial to assess the safety and
toxicity of intraperitoneally administered MOC31PE immunotoxin, given on the 1.postoperative
day after cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
for peritoneal metastases from colorectal cancer (CRC).